TWI293290B - - Google Patents
Download PDFInfo
- Publication number
- TWI293290B TWI293290B TW090126305A TW90126305A TWI293290B TW I293290 B TWI293290 B TW I293290B TW 090126305 A TW090126305 A TW 090126305A TW 90126305 A TW90126305 A TW 90126305A TW I293290 B TWI293290 B TW I293290B
- Authority
- TW
- Taiwan
- Prior art keywords
- crystal
- solvent
- type crystal
- crystals
- type
- Prior art date
Links
- 239000013078 crystal Substances 0.000 claims abstract description 81
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 5
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 3
- 230000002079 cooperative effect Effects 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 abstract 3
- 229960000698 nateglinide Drugs 0.000 abstract 3
- 238000006243 chemical reaction Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000324375 | 2000-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI293290B true TWI293290B (enExample) | 2008-02-11 |
Family
ID=18801920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW090126305A TWI293290B (enExample) | 2000-10-24 | 2001-10-24 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030229249A1 (enExample) |
| EP (1) | EP1334964B1 (enExample) |
| JP (1) | JP4225057B2 (enExample) |
| KR (1) | KR100810930B1 (enExample) |
| CN (1) | CN100422143C (enExample) |
| AT (1) | ATE370115T1 (enExample) |
| AU (1) | AU2001296001A1 (enExample) |
| BR (1) | BR0114846A (enExample) |
| CA (1) | CA2426745C (enExample) |
| CY (1) | CY1106839T1 (enExample) |
| DE (1) | DE60130014T2 (enExample) |
| DK (1) | DK1334964T3 (enExample) |
| ES (1) | ES2288997T3 (enExample) |
| MX (1) | MXPA03003575A (enExample) |
| PT (1) | PT1334964E (enExample) |
| RU (1) | RU2275354C2 (enExample) |
| TW (1) | TWI293290B (enExample) |
| WO (1) | WO2002034713A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001241168B2 (en) * | 2000-03-17 | 2005-06-16 | Ajinomoto Co., Inc. | Drugs for complications of diabetes and neuropathy and utilization thereof |
| MXPA03003484A (es) * | 2000-10-18 | 2003-07-14 | Ajinomoto Kk | Procedimiento para producir cristales de nateglinida. |
| ES2290173T3 (es) * | 2000-10-18 | 2008-02-16 | Ajinomoto Co., Inc. | Procedimiento para la preparacion de acilfenilalaninas. |
| JP4501054B2 (ja) * | 2000-10-24 | 2010-07-14 | 味の素株式会社 | ナテグリニド含有製剤 |
| RU2283104C2 (ru) * | 2000-10-24 | 2006-09-10 | Адзиномото Ко., Инк. | Гидрофильный фармацевтический препарат, содержащий натеглинид |
| JP4538842B2 (ja) * | 2002-04-15 | 2010-09-08 | 味の素株式会社 | 新規ナテグリニド結晶 |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| CA2492644A1 (en) * | 2002-07-18 | 2004-01-29 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) * | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7420084B2 (en) | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| ES2279921T3 (es) * | 2003-11-26 | 2007-09-01 | A.M.S.A. Anonima Materie Sintetiche E Affini S.P.A. | Procedimiento para la preparacion de nateglinida preferentemente en forma b. |
| US20060004102A1 (en) * | 2004-05-07 | 2006-01-05 | Shlomit Wizel | Polymorphic forms of nateglinide |
| US20070231393A1 (en) * | 2004-05-19 | 2007-10-04 | University Of South Carolina | System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles |
| WO2005113485A2 (en) * | 2004-05-20 | 2005-12-01 | Dr. Reddy's Laboratories Ltd. | Stable nateglinide form b compositions |
| US7425648B2 (en) | 2005-01-03 | 2008-09-16 | A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. | Process for the preparation of nateglinide, preferably in B-form |
| WO2006080524A1 (ja) * | 2005-01-31 | 2006-08-03 | Ajinomoto Co., Inc. | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 |
| WO2007135533A1 (en) * | 2006-05-23 | 2007-11-29 | Aurobindo Pharma Limited | Process for preparing nateglinide b-type crystals |
| KR100837843B1 (ko) * | 2006-12-26 | 2008-06-13 | 씨제이제일제당 (주) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 |
| KR20130087485A (ko) | 2010-06-14 | 2013-08-06 | 씨아이피엘에이 엘티디. | 나테글리니드의 제조 방법 |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| CA2873093A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| JP2015519333A (ja) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 神経疾患の治療のための組成物および方法 |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| CA2873084A1 (en) * | 2012-05-08 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| WO2013175357A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory bowel disease |
| US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| CA2873098A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| WO2014037834A2 (en) | 2012-09-08 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| EP3201168B1 (en) | 2014-09-29 | 2020-03-18 | Cellix Bio Private Limited | Compounds and compositions for the treatment of multiple sclerosis |
| AU2014414316B2 (en) | 2014-10-27 | 2020-04-09 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| CN104402756B (zh) * | 2014-11-27 | 2016-08-31 | 天方药业有限公司 | 一种高纯度那格列奈的制备方法 |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CN110845355A (zh) | 2015-01-06 | 2020-02-28 | 塞尔利克斯生物私人有限公司 | 用于治疗炎症和疼痛的组合物和方法 |
| CN109369443A (zh) * | 2018-11-05 | 2019-02-22 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种新的那格列奈h晶型的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| AU615966B2 (en) * | 1987-12-04 | 1991-10-17 | Takeda Chemical Industries Ltd. | Crystals of cephem hydrochloride |
| ES2100291T3 (es) | 1991-07-30 | 1997-06-16 | Ajinomoto Kk | Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos. |
| US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| EP1586314B1 (en) * | 1996-11-15 | 2011-03-30 | Ajinomoto Co., Inc. | Nateglinide tablet composition |
| US6844006B1 (en) * | 1999-07-09 | 2005-01-18 | Pennfield Oil Company | Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions |
| WO2001047557A1 (en) * | 1999-12-28 | 2001-07-05 | Ajinomoto Co., Inc. | Oral preparations for diabetes |
| AU2001241168B2 (en) * | 2000-03-17 | 2005-06-16 | Ajinomoto Co., Inc. | Drugs for complications of diabetes and neuropathy and utilization thereof |
| ES2290173T3 (es) * | 2000-10-18 | 2008-02-16 | Ajinomoto Co., Inc. | Procedimiento para la preparacion de acilfenilalaninas. |
| MXPA03003484A (es) * | 2000-10-18 | 2003-07-14 | Ajinomoto Kk | Procedimiento para producir cristales de nateglinida. |
| JP4501054B2 (ja) * | 2000-10-24 | 2010-07-14 | 味の素株式会社 | ナテグリニド含有製剤 |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
-
2001
- 2001-10-23 RU RU2003111948/04A patent/RU2275354C2/ru not_active IP Right Cessation
- 2001-10-23 MX MXPA03003575A patent/MXPA03003575A/es active IP Right Grant
- 2001-10-23 CA CA002426745A patent/CA2426745C/en not_active Expired - Fee Related
- 2001-10-23 KR KR1020037005671A patent/KR100810930B1/ko not_active Expired - Fee Related
- 2001-10-23 EP EP01976819A patent/EP1334964B1/en not_active Expired - Lifetime
- 2001-10-23 JP JP2002537707A patent/JP4225057B2/ja not_active Expired - Fee Related
- 2001-10-23 AT AT01976819T patent/ATE370115T1/de active
- 2001-10-23 AU AU2001296001A patent/AU2001296001A1/en not_active Abandoned
- 2001-10-23 DE DE60130014T patent/DE60130014T2/de not_active Expired - Lifetime
- 2001-10-23 DK DK01976819T patent/DK1334964T3/da active
- 2001-10-23 CN CNB018212999A patent/CN100422143C/zh not_active Expired - Fee Related
- 2001-10-23 ES ES01976819T patent/ES2288997T3/es not_active Expired - Lifetime
- 2001-10-23 BR BR0114846-0A patent/BR0114846A/pt not_active IP Right Cessation
- 2001-10-23 WO PCT/JP2001/009293 patent/WO2002034713A1/ja not_active Ceased
- 2001-10-23 PT PT01976819T patent/PT1334964E/pt unknown
- 2001-10-24 TW TW090126305A patent/TWI293290B/zh not_active IP Right Cessation
-
2003
- 2003-04-24 US US10/421,888 patent/US20030229249A1/en not_active Abandoned
-
2007
- 2007-06-04 US US11/757,769 patent/US7544834B2/en not_active Expired - Fee Related
- 2007-08-28 CY CY20071101136T patent/CY1106839T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0114846A (pt) | 2004-02-25 |
| DE60130014D1 (de) | 2007-09-27 |
| CA2426745C (en) | 2009-09-15 |
| KR100810930B1 (ko) | 2008-03-10 |
| US20030229249A1 (en) | 2003-12-11 |
| RU2275354C2 (ru) | 2006-04-27 |
| US7544834B2 (en) | 2009-06-09 |
| ES2288997T3 (es) | 2008-02-01 |
| KR20030059212A (ko) | 2003-07-07 |
| ATE370115T1 (de) | 2007-09-15 |
| US20070232829A1 (en) | 2007-10-04 |
| AU2001296001A1 (en) | 2002-05-06 |
| JPWO2002034713A1 (ja) | 2004-03-04 |
| DK1334964T3 (da) | 2007-09-24 |
| EP1334964A4 (en) | 2005-09-28 |
| PT1334964E (pt) | 2007-09-20 |
| CN1483018A (zh) | 2004-03-17 |
| CA2426745A1 (en) | 2003-04-23 |
| CN100422143C (zh) | 2008-10-01 |
| EP1334964A1 (en) | 2003-08-13 |
| DE60130014T2 (de) | 2008-05-08 |
| JP4225057B2 (ja) | 2009-02-18 |
| EP1334964B1 (en) | 2007-08-15 |
| CY1106839T1 (el) | 2012-05-23 |
| WO2002034713A1 (en) | 2002-05-02 |
| MXPA03003575A (es) | 2003-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI293290B (enExample) | ||
| JP3753155B2 (ja) | ４−アセトキシ−２α−ベンゾイルオキシ−５β，２０−エポキシ−１，７β，１０β−トリヒドロキシ−９−オキソ−タキセ−１１−エン−１３α−イル（２Ｒ，３Ｓ）−３−ｔｅｒｔ−ブトキシカルボニアミノ−２−ヒドロキシ−３−フェニルプロピオネート三水和物の製造法 | |
| TW531527B (en) | Novel Modifications of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene, and processes for their preparation | |
| TW200300020A (en) | α-form or β-form crystal of acetanilide derivatives | |
| CN106966947B (zh) | 一种维格列汀的制备方法 | |
| JP2005509025A5 (enExample) | ||
| WO2011054917A1 (en) | Process for the production of polymorph form i of agomelatine | |
| AU2001272872A1 (en) | Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro -2-naphthyl)-4-morpholinobenzamide | |
| EP1305303A1 (en) | NOVEL FORM OF (R)- i N /i - 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE | |
| TW518326B (en) | A process for producing n-(4-fluorophenyl)-n-(1-methylethyl)-2-[(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-oxy]-acetamide | |
| CN117069675A (zh) | 一种非布司他的制备方法 | |
| CN103242291A (zh) | 一种多晶型高含量苯甲酸阿格列汀的批量生产工艺 | |
| JP2019524811A (ja) | ヒドロニドンの製造方法 | |
| JP4080545B2 (ja) | （ｓ）−ｎ，ｎ′−ビス［２−ヒドロキシ−１−（ヒドロキシメチル）エチル］−５−［（２−ヒドロキシ−１−オキソプロピル）アミノ］−２，４，６−トリヨード−１，３−ベンゼンジカルボキシアミドを直鎖状または分岐状の（ｃ５〜ｃ６）アルコールまたはそれらの混合物から結晶化させる方法 | |
| CN106928228A (zh) | 奥格列汀盐及其晶型、它们的制备方法和药物组合物 | |
| JP3208971B2 (ja) | Ｏ，ｏ’−ジアシル酒石酸の製造方法 | |
| WO2014000555A1 (zh) | 制备依非韦伦i型结晶的方法 | |
| CN112358436B (zh) | 一种1,2-环戊二甲酰亚胺的制备方法 | |
| JPS597142A (ja) | γ型グリシンの製造方法 | |
| OA12354A (en) | Tartrate salts of thiazolidinedione derivative. | |
| OA12355A (en) | Tartrate salts of thiazolidinedione derivative. | |
| WO2024188377A2 (zh) | 一种6-甲胺基鸟嘌呤的制备方法 | |
| CN117209454A (zh) | 一种左西替利嗪钠新晶型及其制备方法 | |
| CN118908862A (zh) | 一种氯己定有机酸盐的制备方法 | |
| WO2025193849A1 (en) | Polymorphs of ar-degraders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |